Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. - Ratz,AE.Bravo.; Tchambaz,L.; Krahenbuhl-Melcher,A. (Drug Saf, 2005)